Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Uveal Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Eye Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 5Nivolumab 3Ipilimumab 3lenvatinib 2trametinib 1tislelizumab 1tebentafusp 1spartalizumab 1ruxolitinib 1omipalisib 1binimetinib 1belinostat 1avelumab 1Vorinostat 1Valproic Acid 1Tape Recording 1Sunitinib 1Solutions 1Practice Guidelines as Topic 1Pemetrexed 1Methods 1Melphalan 1Iodized Oil 1Health Promotion 1GSK2141795 1Ethiodized Oil 1Epilim 1Educational Status 1Diet Therapy 1Data Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Uveal Melanoma × belinostat × Clear all
NCT05170334 2026-04-06

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
7 enrolled
Dermatologic

Uveal Melanoma, Eye Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡